Research ArticleClinical Studies

CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy

KAZUKI SONE, TETSUYA OGURI, MAKOTO NAKAO, YUSUKE KAGAWA, RYOTA KUROWAKA, HIROMI FURUTA, SATOSHI FUKUDA, TAKEHIRO UEMURA, OSAMU TAKAKUWA, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, KEN MAENO, YUTAKA ITO, HIDEFUMI SATO, HIDEKI MURAMATSU and AKIO NIIMI
Anticancer Research February 2017, 37 (2) 935-939;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Kaplan–Meier survival curves of progression-free (A) and overall (B) survival according to serum cytokeratin 19 fragment (CYFRA 21-1) level. The median PFS in patients with high and normal serum CYFRA 21-1 levels was 127 days [95% confidence interval (CI)=103-152 days] and 191 days (95% CI=103-349 days), respectively (p=0.046). The median OS in patients with high and normal levels of CYFRA 21-1 was 360 days (95% CI=299-425 days) and 781 days (95% CI=457-1038 days), respectively (p<0.001).

Tables

  • Table I.
  • Table II.
  • Table III.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
KAZUKI SONE, TETSUYA OGURI, MAKOTO NAKAO, YUSUKE KAGAWA, RYOTA KUROWAKA, HIROMI FURUTA, SATOSHI FUKUDA, TAKEHIRO UEMURA, OSAMU TAKAKUWA, YOSHIHIRO KANEMITSU, HIROTSUGU OHKUBO, MASAYA TAKEMURA, KEN MAENO, YUTAKA ITO, HIDEFUMI SATO, HIDEKI MURAMATSU, AKIO NIIMI
Anticancer Research Feb 2017, 37 (2) 935-939;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords